Nutr Res Pract.  2009 Dec;3(4):272-278.

Postprandial hypoglycemic effect of mulberry leaf in Goto-Kakizaki rats and counterpart control Wistar rats

• Park JM
• Bong HY
• Jeong HI
• Kim YK
• Kim JY
• Kwon O

Abstract

Postprandial hypoglycemic effect of mulberry leaf (Morus alba L.) was compared in two animal models: Goto-Kakizaki (GK) rats, a spontaneous non-obese animal model for type II diabetes, and their counterpart control Wistar rats. First, the effect of a single oral administration of mulberry leaf aqueous extract (MLE) on postprandial glucose responses was determined using maltose or glucose as substrate. With maltose-loading, MLE reduced peak responses of blood glucose significantly in both GK and Wistar rats (P < 0.05), supporting the inhibition of alpha-glucosidase by MLE in the small intestine. With glucose-loading, MLE also significantly reduced blood glucose concentrations, measured at 30 min, in both animal models (P < 0.01), proposing the inhibition of glucose transport by MLE. Next, dried mulberry leaf powder (MLP) was administered for 8 weeks by inclusion in the diet. By MLP administration, fasting blood glucose was significantly reduced at weeks 4 and 5 (P < 0.05), but then returned to values that were similar to those of the control at the end of experimental period in GK rats. Insulin, HOMA-IR, C-reactive protein, and triglycerides tended to be decreased by MLP treatment in GK rats. All other biochemical parameters were not changed by MLP administration in GK rats. Collectively, these findings support that MLE has significant postprandial hypoglycemic effect in both non-obese diabetic and healthy animals, which may be beneficial as food supplement to manage postprandial blood glucose. Inhibitions of glucose transport as well as alpha-glucosidase in the small intestine were suggested as possible mechanisms related with the postprandial hypoglycemic effect of MLE.

Keyword

Aqueous mulberry leaf extract; Goto-Kakizaki rats; postprandial hypoglycemic effect

MeSH Terms

Administration, Oral
alpha-Glucosidases
Animals
Blood Glucose
C-Reactive Protein
Diet
Dietary Supplements
Fasting
Glucose
Hypoglycemic Agents
Insulin
Intestine, Small
Maltose
Models, Animal
Morus
Rats
Rats, Wistar
Triglycerides
Blood Glucose
C-Reactive Protein
Glucose
Hypoglycemic Agents
Insulin
Maltose
Triglycerides
alpha-Glucosidases

Figure

• 

  Fig. 1 Effects of MLE on postprandial blood glucose responses in GK rats (A) and their counterpart Wistar (B) rats (n=5 each group). The animals received orally administered maltose (2 g/kg body weight) with or without MLE (3.75 g/kg, 6 mg/kg as DNJ) after overnight fasting for 12h. Blood glucose levels were determined from tail blood samples at 0, 15, 30, 45, 60, 90, and 120 min and incremental blood glucose concentrations (ΔAUC0-2h) were integrated over a period of 2 h (Inset). Comparisons were done between MLE treated (■) and untreated control (□) rats: *P < 0.05, **P < 0.01.

• 

  Fig. 2 Effects of MLE on blood glucose increases 30 min after glucose-loading in GK rats and their counterpart Wistar rats (n=5 each group). The animals received orally administered glucose (2 g/kg) with or without MLE (3.75 g/kg, 6 mg/kg as DNJ) after overnight fasting for 12 h. Blood glucose levels were determined from tail blood samples at 0 and 30 min and the net increases were calculated. Comparisons were done between MLE treated (■) and untreated control (□) rats: **P < 0.01.

• 

  Fig. 3 Effects of MLP on fasting blood glucose concentrations in GK rats (A) and their counterpart Wistar (B) rats (n=10 each group). The animals were fed an AIG-93G diet with or without 10% MLP. The diets were adjusted to provide the same contents of dietary fiber and calories. Fasting blood glucose levels were determined from tail blood sample at fixed times. Comparisons were done between MLP treated and untreated control rats: P < 0.05.

• 

  Fig. 4 Effects of 10% MLP in the diet for 8 weeks on biochemical parameters of blood glucose, lipid, and inflammation control in GK rats and their counterpart Wistar rats (n=10 each group). A: fasting blood glucose (FBG), B: plasma insulin, C: Homeostasis Model Assessment of Insulin Resistance (HOMA-IR), D: Glycated hemoglobin (HbA1C), E: Advanced Glycation End Products (AGEs), F: C-Reactive Protein (CRP), G: Free Fatty Acids (FFAs), H: Triglyceride (TG). Comparisons were done between MLP treated (■) and untreated control (□) rats: P < 0.05.

Reference

1. Andallu B, Varadacharyulu NC. Antioxidant role of mulberry (Morus indica L. cv. Anantha) leaves in streptozotocin-diabetic rats. Clin Chim Acta. 2003. 338:3–10.

2. Andallu B, Varadacharyulu NC. Gluconeogenic substrates and hepatic gluconeogenic enzymes in streptozotocin-diabetic rats: effect of mulberry (Morus indica L.) leaves. J Med Food. 2007. 10:41–48.

3. Asano N, Yamashita T, Yasuda K, Ikeda K, Kameda Y, Kato A, Nash RJ, Lee HS, Ryu KS. Polyhydroxy alkaloids islated from mulberry trees (Morus alba L.) and silkworms (Bombyx mori L.). J Agric Food Chem. 2001. 49:4208–4213.

4. Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care. 1997. 20:1822–1826.

5. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, Hu FB. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. J Am Med Assoc. 2009. 301:2129–2140.

6. Goda T, Suruga K, Komori A, Kuranuki S, Mochizuki K, Makita Y, Kumazawa T. Effects of miglitol, an α-glucosidase inhibitor, on glycaemic status and histopathological changes in islets in non-obese, non-insulin-dependent diabetic Goto-Kakizaki rats. Br J Nutr. 2007. 98:702–710.

7. Goto Y, Efendic S. Abnormal insulin secretion and glucose metabolism in pancreatic islets from the spontaneously diabetic GK rat. Diabetologia. 1993. 36:3–8.

8. Igarashi K, Honma K, Yoshinari O, Nanjo F, Hara Y. Effect of dietary catechins on glucose tolerance, blood pressure and oxidation statues in Goto-Kakizaki rats. J Nutr Sci Vitaminol. 2007. 53:496–500.

9. Janssen U, Phillips AO, Floege J. Rodent models of nephropathy associated with type 2 diabetes. J Nephrol. 1999. 12:159–172.

10. Kim J, Kim S, Lee HS, Kim I, Ahn MY, Ahn MY. Determination of 1-deoxynojirimycin in Morus alba L. leaves by derivatization with 9-fluorenylmethyl chloroformate followed by reversed-phase high-performance liquid chromatography. J Chromatogr A. 2003. 1002:93–99.

11. Kimura T, Nakagawa K, Kubota H, Kojima Y, Goto Y, Yamagishi K, Oita S, Oikawa S, Miyazawa T. Food-grade mulberry powder enriched with 1-deoxynojirimycin suppresses the elevation of postprandial blood glucose in humans. J Agric Food Chem. 2007. 55:5869–5874.

12. Kimura T, Nakagawa K, Saito Y, Yamagishi K, Suzuki M, Yamaki K, Shinmoto H, Miyazawa T. Determination of 1-deoxynojirimycin in Mulberry leaves using hydrophilic interaction chromatography with evaporative light scattering detection. J Agric Food Chem. 2004. 52:1415–1418.

13. Kwon O, Eck P, Chen S, Corpe CP, Lee JH, Kruhlak M, Levine M. Inhibition of the intestinal glucose transporter GLUT2 by flavonoids. FASEB J. 2007. 21:366–377.

14. Lee SK, Hwang JY, Song JH, Jo JR, Kim MJ, Kim ME, Kim JI. Inhibitory activity of Euonymus alatus alpha-glucosidase in vitro and in vivo. Nutr Res Pract. 2007. 1:184–188.

15. Miyahara C, Miyazawa M, Satoh S, Sakai A, Mizusaki S. Inhibitory effects of mulberry leaf extract on postprandial hyperglycemia in normal rats. J Nutr Sci Vitaminol. 2004. 50:161–164.

16. Nakagawa K, Kubota H, Kimura T, Yagashita S, Tsuzuki T, Oikawa S, Miyazawa T. Occurrence of orally administered mulberry1-Deoxynojirimycin in rat plasma. J Agric Food Chem. 2007. 55:8928–8933.

17. Nutrition Research Council. Guide for the care and use of laboratory animals. 1997. 4th Edition. USA: National Academy Press Washington DC.

18. Oku T, Yamada M, Nakamura M, Sadamori N, Nakamura S. Inhibitory effects of extractives from leaves of Morus alba on human and rat small intestinal disaccharidase activity. Br J Nutr. 2006. 95:933–938.

19. Prosky L, Asp NG, Furda I, Devries JW, Schweizer TF, Harland BF. Determination of total dietary fiber in food and food products: Collaborative study. J Assoc Off Anal Chem. 1984. 67:1044–1052.

20. Prosky L, Asp NG, Schweizer TF, Devries JW, Furda I. Determination of insoluble and soluble dietary fiber in foods and food products: collaborative study. J AOAC Int. 1992. 75:360–367.

21. Rother KI. Diabetes treatment-bridging the divide. N Engl J Med. 2007. 356:1499–1501.

22. Voss AA, Diez-Sampedro A, Hirayama BA, Loo DDF, Wright EM. Imino sugars are potent agonists of the human glucose sensor SGLT3. Mol Pharmacol. 2007. 71:628–634.

23. Wheeler ML, Pi-Sunyer FX. Carbohydrate issues: type and amount. J Am Diet Assoc. 2008. 108:S34–S39.

24. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004. 27:1047–1053.

25. Wong JMW, Jenkins DJA. Carbohydrate digestibility and metabolic effects. J Nutr. 2007. 137:2539S–2546S.

26. Yatsunami K, Ichida M, Onodera S. The relationship between 1-deoxynojirimycin content and alpha-glucosidase inhibitory activity in leaves of 276 mulberry cultivars (Morus spp.) in Kyoto, Japan. J Nat Med. 2008. 62:63–66.

27. Zhou YP, Ostenson CG, Ling ZC. Deficiency of pyruvate dehydrogenase activity in pancreatic islets of diabetic GK rats. Endocrinology. 1995. 136:3546–3551.